INTRODUCTION
The use of antithrombotic therapy in hematopoietic progenitor cell transplant patients is complex (Table 1 ). Many aspects of the transplant---thrombocytopenia, gastrointestinal toxicity, polypharmacy with potential for interactions---make such therapy difficult. For complex cardiac or thrombophilic patients, consultation with a cardiology or a hemostasis expert is crucial. Patients receiving these transplants fall into two basic groups regarding antithrombotic therapy---those who are on therapy pre-transplant and those who develop thrombosis during the procedure (Table 2) .
PATIENTS ON ANTITHROMBOTIC THERAPY BEFORE TRANSPLANT
Antiplatelet therapy Coronary artery disease is still the most common cause of death in developed countries and is frequent with an incidence of myocardial infarctions of 5% in patients aged 45--64 years and 14% in patients older than 65 years. 1 Thus, many patients coming for transplant will have silent coronary disease and up to 10% will have a known disease. A significant portion of the population is on aspirin or on other antiplatelet agents. In recent years, the use of these drugs for primary prevention of first myocardial infarction or stroke has become controversial. The absolute reduction in events is very small and almost balanced by the increased risk from bleeding. 2 Therefore, for a transplant patient taking antiplatelet agents for primary prevention, the most reasonable course of action would be to stop the medication.
For secondary prevention, the benefits of antiplatelet therapy are more robust with patients having a 22% reduction in vascular events for secondary prevention of strokes or myocardial infarctions after an initial thrombotic event. 3 If the patient does not have a coronary stent, a reasonable strategy would be to stop the drug when conditioning starts and then resume it when platelets have recovered over 50 Â 10 9 /L. Patient with a history of myocardial infarction, stroke or vascular disease, but not previously on therapy, should be started on 81 mg daily aspirin (or clopidogrel if the patient is aspirin intolerant), when platelets have recovered at 450 Â 10 9 /L levels. The often chosen threshold for aspirin therapy is 50 Â 10 9 /L, despite the lack of data, because this number is the platelet count associated with microvascular bleeding in complex patients. 4 The management of patients with coronary stents is difficult because stopping antiplatelet therapy is strongly associated with stent thrombosis, which can be fatal in up to 50% of the patients. 5 The risk is most extreme for bare metal stents for 4 weeks after placement and with drug-eluting stents up to 1 year after placement. 6 During this at-risk period, even just stopping clopidogrel is associated with adverse outcomes. For a patient with drug-eluting stents, who needs transplantation during the 'at-risk' period, it may be prudent to continue the dual antiplatelet therapy throughout the phase of thrombocytopenia, unless bleeding develops. Consultation with a cardiologist is mandatory before transplantation in a patient with a drug-eluting stent during this at-risk time to fully assess the patient's cardiac risk. For patients with stents outside the at-risk period, continuing aspirin until the platelet count is under 20 Â 10 9 /L and then resuming it when greater than 20 Â 10 9 /L can be considered, as this was the 'inflection point' for increased bleeding in a study of thrombocytopenic patients of whom most were on aspirin. 7 
ANTITHROMBOTIC THERAPY
Choice of therapy during transplantation Although warfarin is the antithrombotic agent of choice for most of the patients requiring anticoagulation, many of its properties make it undesirable for the transplant patient. 8 Warfarin requires close monitoring, has many drug and food interactions, the level of anticoagulation is dependent on vitamin K intake and it has a prolonged biological effect that can take up to 5 days for coagulation factors to return to normal levels. These factors make anticoagulation impractical to quickly start and stop warfarin for changes in clinical condition. The most practical antithrombotic agents for transplantation are the low-molecular-weight heparins (LMWHs). The lack of interactions and the relatively short half-life (B4 h) simplifies their use in this setting. 9 One caution needs to be taken as all the LMWH are renally cleared, hence they need to be closely monitored if used in patients with severe renal insufficiency. There is no clinical trial guidance on what platelet count level is the threshold for anticoagulation, but most experts would recommend no full-dose anticoagulation below a platelet count of 50 Â 10 9 /L and no prophylactic anticoagulation below a platelet count of 20 Â 10 9 /L. 10 This is based on the excess bleeding rates seen in thrombocytopenic patients with hemophilia and in some case series involving transplant patients. 11, 12 In theory, one can give platelet transfusions to patients to try to keep the platelet levels above these thresholds, but in practice this can be difficult and in my experience it can be associated with excess bleeding.
Currently there are new oral anticoagulants in clinical practice and in clinical trials that may offer more choices in the future. 13 Dabigatran---an oral direct thrombin inhibitor---is currently approved for the prevention of stroke in patients with atrial fibrillation and has been shown in a phase III trial to be equivalent to warfarin in the therapy of venous thrombosis. Dosing for both these indications is 150 mg twice daily, if creatinine clearance is greater than 30 ml/min. Unlike warfarin, there are no food interactions. It is not metabolized by cytochromes but is a substrate for the P-glycoprotein transporter. This agent may be an option for the immediate post transplant period after platelet recovery, given the decreased potential for both food and drug interactions. Rivaroxaban is a direct factor Xa inhibitor that also has robust trial data, but given its metabolism via CYP3A4, there is more potential for drug interactions. Given the fact that they are both anticoagulants, prudence would dictate the use of these agents, would follow the same platelet guidelines as for heparin until better data are obtained.
Atrial fibrillation
The leading indication for warfarin in older patients is stroke prevention from atrial fibrillation. It is estimated that 15% of all the strokes can be attributed to atrial fibrillation.
14 Use of warfarin reduces the stroke rate from 5% per year to 1%. While warfarin benefits most patients with atrial fibrillation, patients who previously had strokes appear to benefit the most from anticoagulation. Information now exists to risk-stratify patients and help to choose between warfarin and aspirin therapy. Clinically the most useful prediction rule appears to be the CHADS2 (Table 3) . In this system, one point is given for the presence of congestive heart failure, hypertension, age over 75 years and for the presence of diabetes, and two points are given for history of stroke. 15 A CHADS2 score of 0--2 would suggest low risk of stroke and prophylaxis with aspirin therapy, whereas a higher score supports the use of warfarin. For management of the transplant patient with a CHADS2 score of 0--2, aspirin would be stopped at a platelet count of 50 Â 10 9 /L and resumed when platelets recover to over that level. For patients with higher CHADS2 scores, anticoagulation with LMWH or dabigatran is given as outlined above.
Mechanical cardiac valves
Patients with mechanical heart valves have high risk for embolization or valve thrombosis so anticoagulation is strongly recommended. 16 The estimated risk of thrombosis without anticoagulant ranges from 12 to 30% per year. Findings from clinical studies support the idea that the newer generation of mechanical valves is less thrombogenic than the older ball-cage valves. Even with anticoagulation, the yearly rate of thrombosis ranges from 2.5% with ball-cage to 0.5% with bileaflet valves. Patients with mechanical aortic valves are at lesser risk of thrombosis than those with mechanical mitral valves, and those with atrial fibrillation are at higher risk. However, the rates of embolism and valve thrombosis are still substantial with newer valves and anticoagulation is still mandatory. Although the risk is lower than for mechanical valves, bioprosthetic heart valves still have a definite risk of associated embolization and aspirin therapy is used. 17 The daily risk of stroke in a mechanical valve patient kept off anticoagulation is uncertain, but recent studies suggest it may be as high as 0.5--1%. This risk of potential devastating thrombosis needs to be factored into risk assessment for transplantation. For transplant patients with bioprosthetic valves, one would stop aspirin when the platelet count falls below 50 Â 10 9 /L and resume it when platelets recover to over that level. For patients with higher risk valves, they should be anticoagulated with LMWH as outlined above. To maximize the prevention of thrombotic complications, LMWH levels should be monitored. 18 For the patient perceived to be a very high risk (i.e., mitral valve with atrial fibrillation and history of stroke) a lower platelet threshold of 30 Â 10 9 /L can be used for therapeutic dosing of LMWH and continuing prophylactic dose LMWH throughout the time of severe thrombocytopenia, but this would be associated with the increased risk of bleeding. As platelets are also important for prosthetic valve thrombosis, thrombocytopenia may also offer some very modest protection from valve thrombosis.
Deep venous thrombosis
The duration of therapy for deep vein thrombosis is determined by both the circumstances of the thrombosis and its location. 13 Provoked thrombosis (due to surgery, estrogen, trauma and so on) One point each for recent heart failure, hypertension, age 475 years, and diabetes. Two points assigned for history of stroke. needs only 3 months of anticoagulation, whereas those below the popliteal vein needs at the most 6 weeks. In the patient with idiopathic thrombosis, especially pulmonary embolism, lifelong anticoagulation should be considered. The risk of recurrent thrombosis is thought to be highest at 6--12 weeks after the initial event, hence for most patients---even those requiring longterm anticoagulation---LMWH can be managed as outlined above. For those patients with more complex issues, obtaining the input of a hemostasis consultant will be important to plan the therapy appropriately.
Although rare, deep vein thrombosis can complicate transplantation. Rates are reported to be higher as the patient's blood count recovers and are hospitalized later for complications. Rates of deep venous thrombosis/pulmonary embolism are in the 1.2--5.8% range. 19--21 Given these high rates of thrombosis with hematological malignancies, it may be prudent to offer pharmacological prophylaxis---LMWH, fondaparinux and so on---to all patients, unless there is a specific contraindication such as bleeding or severe thrombocytopenia.
PATIENTS WHO DEVELOP THROMBOSIS DURING TRANSPLANTATION
Catheter thrombosis Central venous catheters are essential in many aspects of cancer therapy. The clinically apparent thrombosis incidence for catheters ranges from 5% to 30% and with screening can be as high as 40% with peripherally inserted central catheters. 22, 23 The incidence of thrombosis is much lower (0.4% vs 7.8%) if tunneled catheters are used instead of mid-line catheters. 24 The difference may be because of peripherally inserted central catheters initiating thrombosis in the veins they are inserted into leading to deeper thrombosis. 25 Signs of catheter thrombosis are nonspecific, leading to the finding that incidence of thrombosis is underestimated and can be as high as 50% if screening is performed. Unlike lower extremity thrombosis, the incidence of pulmonary embolism with upper thrombosis is much less---only 8% vs 31% in one study. 26 Prevention of catheter thrombosis is controversial and most likely futile. 27 Most studies have not shown a benefit of prophylaxis with LMWH or warfarin in preventing thrombosis. One can speculate this lack of effect of prophylaxis is due to the fact that catheter placement leads to direct vascular damage and thrombosis, which cannot be 'overpowered' by prophylaxis.
Although not yet studied in the transplant population, given this information, prophylaxis is not warranted in the transplant setting.
Therapy of central venous catheter thrombosis starts with the removal of the catheter because this will remove the provoker of the thrombus, and is the only clinical step associated with greater recanalization of the vein. 28 If the patient is not severely thrombocytopenic but symptomatic, one can consider anticoagulation for 4--6 weeks. One study attempted to 'salvage' the catheter affected by thrombosis by keeping it in place and using anticoagulation. However, this strategy was associated with a 4% incidence of serious bleeding even in the non-thrombocytopenic patients. 29 Given the low risk of long-term sequelae, there is little indication for thrombolytic therapy. Rarely catheter thrombosis can be a sign of heparin-induced thrombocytopenia as heparin is often used to ensure patency. This diagnosis should be considered if there is massive thrombosis or coincidental thrombosis in other vascular fields.
Deep venous thrombosis
If deep vein thrombosis is diagnosed during the thrombocytopenic phase, those distal to the popliteal vein thrombosis can just be observed with a Doppler scan at 3 days later and then weekly or sooner if the symptoms increase. For the thrombocytopenic patient with a proximal vein thrombosis or pulmonary embolism, many would recommend an inferior vena cava filter be placed until the patient can be anticoagulated. 30 However, given that filters can be a nidus for future thrombosis, some patients can be observed, such as those with small thrombus burden or patients with pulmonary embolism but negative leg scans for thrombosis. 31 Again a threshold of 50 Â 10 9 /L should be used to start anticoagulation. The patient should be anticoagulated for 3 months, since these would be considered thrombosis provoked by their hospital stays and immobility. However, for less straightforward cases, a hemostasis expert should be consulted to help determine the duration, given the need to balance long-term risk of recurrent thrombosis versus hemorrhage. Given the complex medical regimens these patients are on, long-term LMWH or one of the new oral anticoagulants should be used for therapy.
Acute coronary syndrome Modern management of acute coronary syndrome involves intense anticoagulation therapy. The presence of severe thrombocytopenia precludes the use of combined therapy with aspirin, clopidogrel, heparin and i.v. platelet inhibitors. However, the use of aspirin is crucial for any patient with an acute coronary syndrome and should be given to any transplant patient with acute coronary syndrome, no matter what the platelet count is. 32 Further management of the transplant patient with acute coronary syndrome needs to be individualized depending on the stage of transplant they are in and their clinical condition. The cardiologist and the transplant provider need to coordinate care thoroughly in difficult cases.
Future considerations
Introduction of new classes of anticoagulation medications will provide more options for therapy and prophylaxis, as they will have the advantages of being oral agents and more flexible with dosing. The area of prevention of catheter-related thrombosis needs more research to see whether different placement techniques or materials can reduce the rate of thrombosis. Finally more clinical trials in transplant patients are needed to better define the therapy.
